Results 291 to 300 of about 2,295,725 (356)

Cost-effectiveness analysis of nirsevimab for prevention of respiratory syncytial virus disease among infants in Shanghai, China: A modeling study. [PDF]

Hum Vaccin Immunother
Wang Q, Wu J, Li L, Guo Z, Zheng B, Zhang S, Xiang C, Li M, Qiao X, Lv X, Wang W.   +10 more
europepmc   +1 more source

Atrial Fibrillation Screening in the Elderly: A Cost-Effectiveness Analysis for Public Health Policy. [PDF]

JACC Asia
Fu YH, Chao TF, Yeh YH, Chan YH, Chien HT, Chen SA, Lin FJ.   +6 more
europepmc   +1 more source

Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US. [PDF]

PLoS One
Chen P, Qiao D, Xiao L, Deng G, Yang Q, Tian R.   +5 more
europepmc   +1 more source

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. [PDF]

Front Immunol
Zhou Z, Yang Y, Chen S, You M.
europepmc   +1 more source

Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies. [PDF]

Adv Ther
Igarashi A, Tachimori H, Maruyama-Sakurai K, Segawa Y, Takagi H, Akiyama H, Imai N, Kohsaka S, Miyata H.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cost-Effectiveness Analysis 2.0

New England Journal of Medicine, 2017
As prominent groups in U.S. health care ramp up use of cost-effectiveness analysis to measure and communicate the value of new drugs and other interventions, an expert panel has released updated guidelines for such analysis.
Gillian D Sanders, Peter J. Neumann
openaire   +3 more sources

Overview of Cost-effectiveness Analysis

JAMA, 2019
Anirban Basu, Gillian D Sanders, Matthew L. Maciejewski, Matthew L. Maciejewski   +3 more
openaire   +4 more sources